首页> 外文期刊>British Journal of Cancer >Antibody-dependent cellular cytotoxicity to human colon-tumour cells. II. Analysis of the antigens involved
【24h】

Antibody-dependent cellular cytotoxicity to human colon-tumour cells. II. Analysis of the antigens involved

机译:对人结肠肿瘤细胞的抗体依赖性细胞毒性。二。分析涉及的抗原

获取原文
获取外文期刊封面目录资料

摘要

The relationship between carcinoembryonic antigen (CEA) and A antigenic determinants on the cell surface of colon-tumour cells was studied by the ADCC assay. Antiserum prepared in 2 rabbits to an undecapeptide analogous to the amino terminal of CEA(1-11) was found by us either to participate in (Rabbit 2) or specifically inhibit (Rabbit 1) ADCC. The binding spectra of these two antisera and of antiserum to the whole CEA molecule were similar. All of them react with A and non-A colon-tumour cells as well as red blood cells of Type A (RBC-A) and their activity was completely absorbed on RBC-A but not on B or O. O-type, ADCC-reactive human sera always react with A-type colon-tumour cells and RBC-A, and some of them with non-A colon-tumour cells also. The degree of inhibition of their reactivity by anti-CEA(1-11) R1 varied between sera, from none to almost a complete inhibition, and is not related to whether the serum is of cancer or non-cancer origin. Non-reactive O-type sera contain anti-A activity demonstrable by haemagglutination and immunofluorescence. However, they cannot participate in ADCC reaction nor inhibit it. The sera, which contain lymphocyte-dependent antibody to A-type colon-tumour cells, lysed RBC-A, without the addition of lymphocytes or complement, in an immunologically specific way. It is concluded that the reactivity seen in our ADCC system is related to a determinant common to A and CEA (and maybe to other normal cross-reacting antigens) which most probably resides in the amino terminal part of these molecules. This determinant elicits the production of lymphocyte-dependent antibodies in about 50% of people with blood group O. Thus, the amino terminal part of CEA is not a tumour-specific part of the CEA molecule. No specific anti-tumour activity was found in patients' serum by this method, and claims for its demonstration by other methods may well be related to the non-specific activity observed here.
机译:通过ADCC分析研究了癌胚抗原(CEA)和结肠肿瘤细胞细胞表面A抗原决定簇之间的关系。我们发现在2只兔子中制备的类似于CEA(1-11)氨基末端的十一肽的抗血清参与(兔2)或特异性抑制(兔1)ADCC。这两种抗血清和抗血清与整个CEA分子的结合光谱相似。它们都与A和非A结肠肿瘤细胞以及A型红细胞(RBC-A)反应,并且它们的活性完全被RBC-A吸收,但不被B或O吸收。O型,ADCC具有反应活性的人血清总是与A型结肠肿瘤细胞和RBC-A反应,其中一些也与非A结肠肿瘤细胞反应。抗CEA(1-11)R1对它们反应的抑制程度在血清之间变化,从无抑制到几乎完全抑制,并且与血清是癌症还是非癌症无关。非反应性O型血清包含可通过血凝和免疫荧光证明的抗A活性。但是,它们既不能参与ADCC反应,也不能抑制它。含有针对A型结肠肿瘤细胞的淋巴细胞依赖性抗体的血清以免疫学特异性方式裂解了RBC-A,而未添加淋巴细胞或补体。结论是,在我们的ADCC系统中看到的反应性与A和CEA共同的决定因素(可能与其他正常的交叉反应抗原)有关,该决定因素很可能位于这些分子的氨基末端。该决定因素在大约50%的血型为O的人群中引起淋巴细胞依赖性抗体的产生。因此,CEA的氨基末端部分不是CEA分子的肿瘤特异性部分。通过这种方法在患者的血清中未发现特异性抗肿瘤活性,通过其他方法证明其抗肿瘤活性的主张可能与此处观察到的非特异性活性有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号